Abstracts tagged "Abatacept"

Abstract Number: 115 • 2018 ACR/ARHP Annual Meeting
CTLA4-Ig/CD86 Interaction on Cultered Human Fibrocytes and Fibroblasts from Systemic Sclerosis Patients
Maurizio Cutolo¹, Paola Montagna², Stefano Soldano¹, Amelia Chiara Trombetta³, Barbara Ruaro⁴, Paola Contini⁵, Sabrina Paolino⁶, Carmen Pizzorni⁴, Elisa Alessandri⁴, Massimo Patanè¹, Alberto Sulli⁴, Stefano Scabini⁷, Emanuela Stratta⁷ and Renata Brizzolara¹, ¹Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Polyclinic San Martino Hospital, Genova, Italy, Genoa, Italy, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genova, Italy, ³Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, IRCCS Polyclinic San Martino, University of Genoa, Genoa, Italy, ⁴Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genoa, Italy, ⁵Division of Clinical Immunology, Department of Internal Medicine, University of Genova, IRCCS Polyclinic San Martino, Genova, Italy, Genova, Italy, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, San Martino Polyclinic Hospital, Genoa, Italy, Genova, Italy, ⁷Oncologic Surgery, Department of Surgery, IRCCS Polyclinic San Martino, Genova, Italy, Genoa, Italy
Background/Purpose: CTLA4-Ig interacts with the cell surface costimulatory molecule CD86 and can downregulate the target cell activation [1]. Circulating fibrocytes (CFs) express markers of both…
Abstract Number: 563 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety of Abatacept in Combination with MTX in Early, MTX-Naïve, Anti-Citrullinated Protein Antibody–Positive Patients with RA: Primary and 1-Year Results from a Phase IIIb Study
Paul Emery¹, Yoshiya Tanaka², Vivian P. Bykerk³, Tom W.J. Huizinga⁴, Gustavo Citera⁵, Marleen Nys⁶, Sean E. Connolly⁷, Alyssa Johnsen⁷ and Roy Fleischmann⁸, ¹University of Leeds and Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Hospital for Special Surgery, New York, NY, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ⁶Bristol-Myers Squibb, Braine L’Alleud, Belgium, ⁷Bristol-Myers Squibb, Princeton, NJ, ⁸Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: In patients (pts) with early (disease duration ≤24 months [mths]), MTX-naïve RA and poor prognostic factors including anti-citrullinated protein antibody (ACPA) positivity (+), abatacept…
Abstract Number: 900 • 2018 ACR/ARHP Annual Meeting
Abatacept Vs. Placebo in Early Diffuse Cutaneous Systemic Sclerosis— Results of a Phase 2 Investigator Initiated, Double-Blind, Placebo-Controlled, Multicenter, Randomized Controlled Trial Study
Dinesh Khanna¹, Cathie Spino², Erica Bush³, Sindhu Johnson⁴, Lorinda Chung⁵, Jerry Molitor⁶, Virginia D. Steen⁷, Robert Lafyatis⁸, Robert W. Simms⁹, Christopher P. Denton¹⁰, Suzanne Kafaja¹¹, Tracy M. Frech¹², Vivien Hsu¹³, Robyn T. Domsic¹⁴, Janet E. Pope¹⁵, Jessica K. Gordon¹⁶, Maureen D. Mayes¹⁷, Elena Schiopu³, Amber Young¹, Nora Sandorfi¹⁸, Jane Park¹⁹, Faye N. Hant²⁰, Elana J. Bernstein²¹, Soumya Chatterjee²², Flavia V. Castelino²³, Ali Ajam²⁴, Yannick Allanore²⁵, Marco Matucci-Cerinic²⁶, Oliver Distler²⁷, Ora Singer²⁸, Haoyan Zhong², David Fox²⁹ and Daniel E. Furst³⁰, ¹Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ²Biostatistics, University of Michigan, Ann Arbor, MI, ³University of Michigan, Ann Arbor, MI, ⁴Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁵Immunology and Rheumatology, Stanford University School of Medicine, Palo Alto, CA, ⁶Rheumatic & Autoimmune Diseases, University of Minnesota, Minneapolis, MN, ⁷Rheumatology, MedStar Georgetown University Hospital, Washington, DC, ⁸Medicine/Division of Rheumatology, Pittsburgh University Medical Center, Pittsburgh, PA, ⁹Rheumatology, Boston University School of Medicine, Boston, MA, ¹⁰UCL Division of Medicine, Royal Free Campus, London, United Kingdom, ¹¹Department of Internal Medicine, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology, Los Angeles, CA, ¹²Division of Rheumatology, University of Utah, Salt Lake City, UT, ¹³Rheumatology, Robert Wood Johnson University Scleroderma Program, New Brunswick, NJ, ¹⁴Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹⁵Department of Medicine, University of Western Ontario, London, ON, Canada, ¹⁶Rheumatology, Hospital for Special Surgery, New York, NY, ¹⁷Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁸Perelman School of Medicine, University of Pennsylvania, Pittsburgh, PA, ¹⁹Seattle Rheumatology Associates, Seattle, WA, ²⁰Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, ²¹Rheumatology, Columbia University, New York, NY, ²²Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ²³Rheumatology, Harvard Medical School, Boston, MA, ²⁴Division of Rheumatology-Immunology, The Ohio State University Wexner Medical Center, Columbus, OH, ²⁵Service de Rhumatologie A, Hôpital Cochin, Paris, France, ²⁶Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²⁷Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ²⁸Medicine, University of Michigan, Ann Arbor, MI, ²⁹Internal Medicine, University of Michigan, Ann Arbor, MI, ³⁰UCLA, Los Angeles, CA
Background/Purpose: Abatacept (ABA) is a recombinant fusion protein including extracellular domain of human CTLA4 and hinge‑ CH2‑CH3 of the Fc domain of human IgG. This…
Abstract Number: 971 • 2018 ACR/ARHP Annual Meeting
A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Abatacept or Placebo on Standard of Care in Patients with Active Class III or IV Lupus Nephritis
Mary A. Dooley¹, Gerald B. Appel², Richard Furie³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Ayanbola Elegbe¹⁰, David Jayne¹¹ and Michael A. Maldonado¹⁰, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Columbia University Medical Center, New York, NY, ³Northwell Health, New York, NY, ⁴University of California San Francisco, San Francisco, CA, ⁵Keio University School of Medicine, Tokyo, Japan, ⁶Nephrology Division, Hospital Fernández, Buenos Aires, Argentina, ⁷Division of Rheumatology, University of Padova, Padova, Italy, ⁸Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Bristol-Myers Squibb, Princeton, NJ, ¹¹University of Cambridge, Cambridge, United Kingdom
Background/Purpose: The tenets of novel treatment (tx) strategies for active class III/IV lupus nephritis (LN) aim to improve renal response rates, decrease extra-renal SLE disease…
Abstract Number: 1469 • 2017 ACR/ARHP Annual Meeting
Treatment Paradigms in Real-World Practice: Biologic Agent Use Prior to and after Discontinuation of Abatacept
Rieke Alten¹, H-M Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, Y Elbez⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: ACTION is a 2-year, observational study of patients (pts) with moderate-to-severe RA who initiated IV abatacept in Canada and Europe (NCT02109666). The objective was…
Abstract Number: 1817 • 2017 ACR/ARHP Annual Meeting
Abatacept Shows Better Sustainability Than TNF Inhibitors When Used Following Initial Biologic DMARD Failure in the Treatment of RA: 8 Years of Real-World Observations from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, L Bessette², E Alemao³, B Haraoui⁴, F Massicotte¹, M Mtibaa⁵, E Muratti⁵, Jean-Pierre Pelletier¹, R Postema⁶, Jean-Pierre Raynauld⁷, M-A Rémillard⁸, D Sauvageau¹, A Turcotte⁹, É Villeneuve¹ and L Coupal¹⁰, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁵Bristol-Myers Squibb, Montréal, QC, Canada, ⁶Bristol-Myers Squibb, Uxbridge, United Kingdom, ⁷Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁸Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ⁹Rheumatology, Centre d’Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada, ¹⁰Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada
Background/Purpose: In the absence of biomarkers predicting response to a specific therapy, the choice of second biologic is based mostly on habit and availability of…
Abstract Number: 2272 • 2017 ACR/ARHP Annual Meeting
Long-Term Effectiveness and Safety of Abatacept in Juvenile Idiopathic Arthritis: Ongoing Results from the Abatacept in JIA Registry
Daniel J Lovell¹, N Ruperto², N Tzaribachev³, A Zeft⁴, Rolando Cimaz⁵, V Stanevica⁶, Gerd Horneff⁷, John F. Bohnsack⁸, Thomas A. Griffin⁹, R Carrasco¹⁰, Maria Trachana¹¹, Jason A Dare¹², I Foeldvari¹³, Richard K Vehe¹⁴, TA Simon¹⁵, Hermine I. Brunner¹⁶ and Alberto Martini², ¹Cincinnati Children’s Hosp. Medical Center, Cincinnati, OH, ²Istituto G. Gaslini Pediatria II Reumatologia, Genova, Italy, ³University Medical Center Schleswig-Holstein, Bad Bramstedt, Germany, ⁴Cleveland Clinic, Cleveland, OH, ⁵Azienda Ospedaliero-Universitaria Meyer, Florence, Italy, ⁶Riga Stradins University, Riga, Latvia, ⁷Asklepios Klinik Zentrum für Allgemeine Paediatrie und Neonatologie, Sankt Augustin, Germany, ⁸University of Utah School of Medicine, Salt Lake City, UT, ⁹Levine Children’s Hospital at Carolinas Medical Center, Charlotte, NC, ¹⁰Specially For Children, Austin, TX, ¹¹Hippokration General Hospital, Thessaloniki, Greece, ¹²University of Arkansas for Medical Sciences, Little Rock, AR, ¹³Hamburg Centre for Pediatric Rheumatology, Hamburg, Germany, ¹⁴University of Minnesota, Minneapolis, MN, ¹⁵Bristol-Myers Squibb, Princeton, NJ, ¹⁶Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Abatacept is an FDA- and EMA-approved biologic that is widely used in children with juvenile idiopathic arthritis (JIA). The purpose of this long-term ongoing…
Abstract Number: 2450 • 2017 ACR/ARHP Annual Meeting
Comparative Effectiveness of Abatacept Versus TNFi in Patients with RA Who Are CCP+ in the United States Corrona Registry
Leslie R Harrold¹, Heather J. Litman², SE Connolly³, E Alemao³, K Price³, S Kelly³, Sabrina Rebello⁴, W Hua² and Joel Kremer⁵, ¹University of Massachusetts, Worcester, MA, ²Corrona, Southborough, MA, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY
Background/Purpose: Anti-cyclic citrullinated peptide positivity (CCP+) is associated with a better response to abatacept than anti-CCP negativity in patients with RA1,2; however, there are no…
Abstract Number: 2452 • 2017 ACR/ARHP Annual Meeting
In Real-World Clinical Practice, Patients Switching from IV to SC Abatacept Maintain Clinical Efficacy after Switch
Rieke Alten¹, HM Lorenz², X Mariette³, H Nüßlein⁴, M Galeazzi⁵, F Navarro⁶, M Chartier⁷, J Heitzmann⁸, C Rauch⁹ and M Le Bars⁷, ¹Schlosspark-Klinik University Medicine, Berlin, Germany, ²University Hospital, Heidelberg, Germany, ³Université Paris-Sud, Paris, France, ⁴University of Erlangen-Nuremberg, Nuremberg, Germany, ⁵University of Siena, Siena, Italy, ⁶Hospital Universitario Virgen Macarena, Seville, Spain, ⁷Bristol-Myers Squibb, Rueil-Malmaison, France, ⁸Excelya, Boulogne-Billancourt, France, ⁹Bristol-Myers Squibb, Munich, Germany
Background/Purpose: Patients (pts) with RA may be able to switch from IV to SC abatacept with no loss of efficacy or safety concerns, but data…
Abstract Number: 419 • 2017 ACR/ARHP Annual Meeting
Abatacept Initiation in Chilean Patients with Long Lasting Rheumatoid Arthritis. Hospital Padre Hurtado Experience
Omar Valenzuela¹, María Paz Poblete², Claudia Mardones², Sebastián Ibáñez¹, Katherine Mogollones², Francisco Silva¹ and María José Villar², ¹Rheumatology department, Hospital Padre Hurtado, Santiago, Chile, ²Hospital Padre Hurtado, Santiago, Chile
Background/Purpose: Since the year 2016 Rheumatoid Arthritis (RA) patients in the Chilean public health system can access biologic treatment if they have active disease refractory…
Abstract Number: 2491 • 2017 ACR/ARHP Annual Meeting
Real-World Effectiveness and Safety of Subcutaneous Abatacept in Biologic-Naive Vs. Biologic-Experienced RA Patients: The Abatacept Best Care Study
B Haraoui¹, Janet E. Pope², Isabelle Fortin³, Emmanouil Rampakakis⁴, John S. Sampalis^5,6, Francoise Romeyer⁷, Joseph Atallah⁷ and Louis Bessette⁸, ¹Institut de Recherche en Rhumatologie de Montréal (IRRM), Montreal, QC, Canada, ²Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ³Centre de Rhumatologie de l'Est du Quebec, Rimouski, QC, Canada, ⁴JSS Medical Research, Montreal, QC, Canada, ⁵McGill University, Montreal, QC, Canada, ⁶JSS Medical Research, St-Laurent, QC, Canada, ⁷Bristol-Myers Squibb, Montreal, QC, Canada, ⁸Centre d'Osteoporose et de Rhumatologie de Quebec, Quebec, QC, Canada
Background/Purpose: The efficacy and safety of subcutaneous (SC) abatacept in the management of rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. However,…
Abstract Number: 498 • 2017 ACR/ARHP Annual Meeting
Response to Abatacept of Different Patterns of Interstitial Lung Disease in Rheumatoid Arthritis. Multicenter Study of 63 Patients
Carlos Fernández-Díaz¹, Santos Castañeda², Clara Ojeda-Garcia³, Alejandro Olivé⁴, Patricia Carreira⁵, Trinidad Perez Sandoval⁶, Miriam Retuerto Guerrero⁷, Evelin Cecilia Cervantes Pérez⁸, Samantha Rodriguez⁹, Bryan Josue Robles Flores¹⁰, Blanca Hernández-Cruz¹¹, Ana Urruticoechea-Arana¹², Olga Maiz¹³, Desiree Palma¹⁴, Luis Arboleya¹⁵, Gema Bonilla¹⁶, Manuel Rodríguez-Gómez¹⁷, Concepción Delgado¹⁸, Rosa Expósito¹⁹, Ana Ruibal Escribano²⁰, Juan Blanco Madrigal²¹, José Antonio Bernal²², Paloma Vela²³, Belen Alvarez-Rodriguez²⁴, María Concepción Fito Manteca²⁵, Javier Narváez²⁶, Manuel Jose Moreno²⁷, Mireia López-Corbeto²⁸, Natalia Mena-Vazquez²⁹, S. Romero-Yuste³⁰, Clara Aguilera-Cros³¹, Sergi Ordoñez³², Ignacio Villa-Blanco³³, Nuria Vegas-Revenga¹, Victor Mora-Cuesta³⁴, Javier Loricera¹, Miguel Angel González-Gay¹, José Luis Hernandez³⁵ and Ricardo Blanco¹, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Universidad de Cantabria. Spain, Santander, Spain, ²Hospital Universitario de La Princesa, Madrid. Spain, Madrid, Spain, ³Rheumatology, Hospital Virgen de la Macarena, Sevilla, Spain, ⁴Rheumatology, Hospital Germans Trias i Pujol, Badalona, Spain, ⁵Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, ⁶Rheumatology, Hospital de León, LEÓN, Spain, ⁷Rheumatology, Hospital de León, Leon, Spain, ⁸Rheumatology, Hospital Santiago de Compostela, Santiago de Compostela, Spain, ⁹H. German Trias., Barcelona, Spain, ¹⁰Rheumatology, Hospital Universitario Puerta de Hierro Majadahonda, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Virgen Macarena, Sevilla, Spain, ¹²Rheumatology Department. Hospital Can Misses, IBIZA, Spain, ¹³Hospital Donostia. Spain, San Sebastian, Spain, ¹⁴Rheumatology, Rafael Mendez Hospital, Spain., Lorca (Murcia), Spain, ¹⁵Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Hospital Universitario La Paz, Madrid, Spain, ¹⁷Complejo Hospitalario Universitario de Ourense, Ourense, Spain, ¹⁸H. Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹⁹Rheumatology, Hospital Comarcal de Laredo. Spain, Laredo, Spain, ²⁰Rheumatology, Hospital Universitario de Araba, Vittoria, Spain, ²¹Rheumatology, Hospital de Basurto, BIlbao, Spain, ²²Reumatología, Hospital Universitario del Vinalopó, Elche, Spain, ²³Reumatología, Hospital General Universitario de Alicante. Alicante. Spain, Alicante, Spain, ²⁴Hospital Txagorritxu, Vittoria, Spain, ²⁵Reumatología, Hospital de Navarra, Pamplona, Spain, ²⁶Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²⁷Rheumatology, Hospital Virgen de la Arrixaca, MURCIA, Spain, ²⁸Hospital Universitario Vall d´Hebron, Barcelona, Spain, ²⁹Rheumatology, Hospital Universitario de Malaga, Malaga, Spain, ³⁰H. Pontevedra, Pontevedra, Spain, ³¹Rheumatology, Hospital Virgen del Rocio, Sevilla, Spain, ³²Hospital Universitario Arnau de Vilanova, Vilanova, Spain, ³³Hospital de Sierrallana, Sierrallana, Spain, ³⁴Neumology, Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain, ³⁵Division of Internal Medicine., Hospital Universitario Marqués de Valdecilla, IDIVAL,, Santander, Spain
Background/Purpose: Disease modifying antirheumatic drugs (DMARD) such as methotrexate (MTX), ) or antiTNFα have been implicated in exacerbation of Interstitial lung disease (ILD)of rheumatoid arthritis…
Abstract Number: 2494 • 2017 ACR/ARHP Annual Meeting
Analysis of the Efficacy, Safety and Continuation Rate of Abatacept in Elderly Patients with Rheumatoid Arthritis
Mayumi Matsuda¹, Yu Funakubo Asanuma², Noritsune Kouzu³ and Toshihide Mimura², ¹Department of Rheumatology and Applied Immunology, Saitama Medical University, Moroyama-machi, Japan, ²Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, ³Saitama Medical University, Moroyama, Japan
Background/Purpose: The elderly rheumatoid arthritis (RA) patients have declined physical performances and various complications. The efficacy of the biological DMARDs may decrease in elderly RA…
Abstract Number: 526 • 2017 ACR/ARHP Annual Meeting
Comparative Pulmonary Safety of Abatacept and Tumor Necrosis Factor Inhibitors in Patients with RA and Chronic Pulmonary Condition
Eun Ha Kang¹, Yinzhu Jin², Sara Dejene³, Gregory Brill³, Rishi J. Desai², Jeffrey A. Sparks⁴ and Seoyoung C. Kim⁵, ¹Division of Rheumatology, Department of Internal Medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea, Republic of (South), ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women’s Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Rheumatology, Immunology and Allergy; Pharmacoepidemiologyand Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Patients with rheumatoid arthritis (RA) can have various pulmonary comorbidities including asthma, chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD). Biologics can…
Abstract Number: 2786 • 2017 ACR/ARHP Annual Meeting
Timing of Abatacept Infusions before Elective Arthroplasty and the Risk of Post-Operative Infection
Michael D. George¹, Joshua Baker², Kevin Winthrop³, E Alemao⁴, Lang Chen⁵, SE Connolly⁴, TA Simon⁴, Qufei Wu⁶, Fenglong Xie⁷, Shuo Yang⁷ and Jeffrey R. Curtis⁸, ¹Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³Oregon Health Sciences University, Portland, OR, ⁴Bristol-Myers Squibb, Princeton, NJ, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Biostatistics and Analysis Center, University of Pennsylvania, Philadelphia, PA, ⁷Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Current guidelines recommend holding biologic DMARDs before major surgery, despite limited data. Few studies have examined perioperative timing of individual biologic therapies. This study…